RTW Investments is taking its Yarrow Bioscience vehicle public through a reverse merger with Vyne Therapeutics and plans a substantial cash infusion to scale the biotech. Yarrow will acquire Vyne’s Nasdaq listing while RTW’s Yarrow Bioscience becomes the public entity, a structure designed to accelerate clinical and commercial work and bring new capital to the pipeline. The transaction includes a $200 million cash infusion and an all-stock swap that hands Vyne’s exchange spot to Yarrow’s management. RTW intends to use the proceeds to advance lead programs and support business development, positioning the newly public company for near-term dealmaking and clinical milestones.